Intracoronary epinephrine and verapamil in the refractory no-reflow phenomenon in patients with acute myocardial infarction
https://doi.org/10.15829/1728-8800-2022-2936
Abstract
Despite modern advances in performing percutaneous coronary interventions, refractory no-reflow remains a serious problem that worsens in-hospital and long-term prognosis. Low-dose adrenaline may exhibit potent beta-receptor agonist properties that mediate coronary vasodilation.
Aim. To evaluate the efficacy and safety of intracoronary administration of epinephrine and verapamil, as well as their combination, compared with standard treatment in patients with ST-segment elevation myocardial infarction (STEMI) and refractory no-reflow during percutaneous coronary interventions.
Material and methods. Patients with STEMI and refractory no-reflow will be randomized into 4 groups: standard therapy, intracoronary adrenaline, intracoronary verapamil, intracoronary epinephrine + verapamil. All patients will be assessed for epicardial blood flow using the Thrombolysis in Myocardial Infarction (TIMI) and Myocardial Blush Grade (MBG) scales, peak troponin levels, ST segment changes, echocardiography, magnetic roesnance imaging, and dynamic single photon emission computed tomography.
Results. Based on the pharmacodynamic effects of epinephrine and verapamil, their combination is expected to have a more potent vasodilating effect.
Conclusion. If the Intracoronary administration of EPInephrine and VERapamil in the refractory no-reflow phenomenon (EPIVER) study will be successful, a novel, more effective method for managing refractory no-reflow phenomenon will appear. This will ensure better preservation of left ventricular systolic function, as well as improve the prognosis and clinical course of the disease.
About the Authors
S. V. Dil
Cardiology Research Institute, Tomsk National Research Medical Center
Russian Federation
Russian Federation
Stanislav Viktorovic Dil
111a Kievskya Street, 634012 Tomsk
E. V. Vyshlov
Cardiology Research Institute, Tomsk National Research Medical Center
Russian Federation
Russian Federation
Evgeny V. Vyshlov
111a Kievskya Street, 634012 Tomsk
V. V. Ryabov
Cardiology Research Institute, Tomsk National Research Medical Center
Russian Federation
Russian Federation
Vyacheslav V. Ryabov
111a Kievskya Street, 634012 Tomsk
References
1. Levine GN, Bates ER, Blankenship JC, et al. 2015 ACC/AHA/ SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction — a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the society for cardiovascular angiography and interventions. Catheter Cardiovasc Interven. 2016;87(6):1001-19. doi:10.1002/ccd.26325.
2. Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with STsegment elevation of the European society of cardiology (ESC). Eur Heart J. 2018;39(2):119-77. doi:10.1093/eurheartj/ehx393.
3. Rezkalla SH, Stankowski RV, Hanna J, Kloner RA. Management of no-reflow phenomenon in the catheterization laboratory. JACC Cardiovasc Interv. 2017;10:215-23. doi:10.1016/j.jcin.2016.11.059.
4. Ibanez B, Heusch G, Ovize M, Van de Werf F. Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardiol. 2015;65(14):1454-71. doi:10.1016/j.jacc.2015.02.032.
5. Hausenloy DJ, Botker HE, Engstrom T, et al. Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations. Eur Heart J. 2017;38(13):935-41. doi:10.1093/eurheartj/ehw145.
6. Akturk IF, Yalcin AA, Biyik I, et al. Effects of verapamil and adenosine in an adjunct to tirofiban on resolution and prognosis of no-reflow phenomenon in patients with acute myocardial infarction. Minerva Cardioangiol. 2014;62:389-97.
7. Salinas P, Jimenez-Valero S, Moreno R, et al. Update in pharmacological management of coronary no-reflow phenomenon. Cardiovasc Hematol Agents Med Chem. 2012;10:256-64. doi:10.2174/187152512802651024.
8. Zhao YJ, Fu XH, Ma XX, et al. Intracoronary fixed dose of nitroprusside via thrombus aspiration catheter for the prevention of the no-reflow phenomenon following primary percutaneous coronary intervention in acute myocardial infarction. Exp Ther Med. 2013;6:479-84. doi:10.3892/etm.2013.1139.
9. Westfall TCWD. Adrenergic agonists and antagonists. In: Brunton L, ed. Goodman and Gilman’s Pharmacologic basis of therapeutics. 12th ed. New York: McGraw-Hill. 2018;191-225.
10. Skelding KA, Goldstein JA, Mehta L, et al. Resolution of refractory no-reflow with intracoronary epinephrine. Catheter Cardiovasc Interven. 2002;57:305-9. doi:10.1002/ccd.10303.
11. Navarese EP, Frediani L, Kandzari DE, et al. Efficacy and safety of intracoronary epinephrine versus conventional treatments alone in STEMI patients with refractory coronary no-reflow during primary PCI: The RESTORE observational study. Catheter Cardiovasc Interv. 2020;1-10. doi:10.1002/ccd.29113.
12. Wang L, Cheng Z, Gu Y, Peng D. Short-Term Effects of Verapamil and Diltiazem in the Treatment of No Reflow Phenomenon: A Meta-Analysis of Randomized Controlled Trials. BioMed Res Int. 2015;2015:382086. doi:10.1155/2015/382086.
13. Aksu T, Guler TE, Colak A, et al. Intracoronary epinephrine in the treatment of refractory no-reflow after primary percutaneous coronary intervention: a retrospective study. BMC Cardiovasc Disord. 2015;15:10. doi:10.1186/s12872-015-0004-6.
14. Taniyama Y, Ito H, Iwakura K, et al. Beneficial Effect of Intracoronary Verapamil on Microvascular and Myocardial Salvage in Patients with Acute Myocardial Infarction. JACC. 1997;30 (5):1193-9. doi:10.1016/s0735-1097(97)00277-5.
15. Bland JM, Altman DG. Statistical method for assessing agreement between two methods of clinical measurement. Lancet. 1986;i:307-10.
16. Lu MJ, Zhong WH, Liu YX, et al. Sample size for assessing agreement between two methods of measurement by BlandAltman method. Int J Biostat. 2016;12(2):20150039. doi:10.1515/ijb-2015-0039.
17. Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149(2):209-16. doi:10.1016/j.ahj.2004.08.005.
18. Simes RJ, Topol EJ, Holmes DR, et al. Link between the angiographic sub study and mortality outcomes in a large randomized trial of myocardial reperfusion: Importance of early and complete infarct artery reperfusion. Circulation. 1995;91:1923-8. doi:10.1161/01.cir.91.7.1923.
19. Yano A, Ito H, Iwakura K, et al. Myocardial contrast echocardiography with a new calibration method can estimate myocardial viability in patients with myocardial infarction. J Am Coll Cardiol. 2004;43:1799-806. doi:10.1016/j.jacc.2003.10.069.
20. Ito H, Maruyama A, Takiuchi S, et al. Clinical implications of the no-reflow phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation. 1996;93:223-8. doi:10.1161/01.CIR.93.2.223.
Supplementary files
Review
For citations:
Dil S.V., Vyshlov E.V., Ryabov V.V. Intracoronary epinephrine and verapamil in the refractory no-reflow phenomenon in patients with acute myocardial infarction. Cardiovascular Therapy and Prevention. 2022;21(1):2936. https://doi.org/10.15829/1728-8800-2022-2936
Views:
1022
Email this article 
